Non-small cell carcinoma that harbor an activating mutation in the epidermal growth factor receptor (EGFR) kinase domain are associated with sensitivity to tyrosine kinase inhibitor (TKIs) [1, 2]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.